The phase III JUNIPER trail in KRAS‐mutant Stage IV NSCLC showed that median PFS, response rate, and disease control rate were better with abemaciclib, a third‐generation CDK inhibitor compared to erlotinib. This evidence concerns the gene KRAS and non-small cell lung carcinoma.